Developing a MAb Aggregate Removal Step by High Throughput Process Development - High throughput process development allows rapid screening of chromatographic parameters. - BioPharm International

ADVERTISEMENT

Developing a MAb Aggregate Removal Step by High Throughput Process Development
High throughput process development allows rapid screening of chromatographic parameters.


BioPharm International
Volume 23, Issue 4

OPTIMIZATION OF FLOW-THROUGH PURIFICATION

A further screening in 96-well plate format was performed for all these media to identify the chromatographic conditions to reduce the aggregate levels to <1%. The starting material had very low levels of HCPs, so these were not considered in this particular study.


Table 3. Screening conditions for flow-through purification
The MAb was loaded on the chromatography media in a range of pH values and NaCl concentrations (Table 3). After 60 min of incubation with the sample (5.3 g/L), the flow-through fractions were collected and the concentration of monomer and aggregates in the fractions was determined by SEC.




Using the monomer and aggregate concentration in the starting material (C ini,m , Cini,a) and the concentration in the flow-through fraction (Cm,Ca), the binding capacity for monomer (Qm) and for the aggregates (Qa) can be calculated according to the following equation:

For the strong anion exchanger (Capto Q), the highest capacity for both monomer and aggregates was observed at high pH values and the lowest NaCl concentration (data not shown). For all conditions, the monomer capacity was higher than the aggregate capacity. The capacity for the weak anion exchanger (Capto DEAE) leveled off at higher pH levels (8.8–9.2, data not shown). This is thought to be because of the nature of the DEAE ligand, which loses its charge around this pH, while the quaternary ammonium ions remain charged at these conditions.


Figure 1
The calculations with the multimodal medium (Capto adhere) revealed the highest capacity for both monomer and aggregates at high pH values and low NaCl concentrations, as shown in Figure 1. For phosphate, the capacity decreased with increasing NaCl concentration, and the opposite trend was seen for citrate. Given that this was a flow-through step, the objective was to identify conditions when the aggregate capacity was much higher than the monomer capacity. For all conditions, the monomer capacity was higher than the aggregate capacity, which would mean a low monomer yield in a flow-through step.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here